Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramelteon SL in Maintenance Treatment of Bipolar I Disorder
NCT01467713Phase 3Terminated
- Sponsor
- Takeda
- Start
- Dec 2011
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of ramelteon in bipolar I disorder (4 arms), sponsored by Takeda. Primary endpoint: Time From Randomization to Any Relapse at 12 months. Started Dec 2011; status: terminated.
02
Drugs
ramelteon
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT01467713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01467713.